Micali G, Nasca M R, Tedeschi A, Dall'Oglio F, Pulvirenti N
Dermatology Clinic, University of Catania, Catania, Italy.
Pediatr Dermatol. 2000 Jul-Aug;17(4):315-8. doi: 10.1046/j.1525-1470.2000.01762.x.
We evaluated the efficacy of squaric acid dibutylester (SADBE) contact immunotherapy for the treatment of warts on a series of 188 children. Included in the study were those children who satisfied at least two of the following criteria: single or multiple sites with several warts, warts resistant to repeated medical and/or surgical treatments, recurrent multiple warts, and patient or parent refusal to undergo destructive or surgical treatment. Excluded from the study were children with single warts or with flat warts located exclusively on the face and children less than 2 years of age. Treatment consisted of twice weekly applications of serial dilutions of SADBE (0.03-3%) for no more than 10 weeks. Of the 148 children who completed the study, 124 (84%) showed complete clinical resolution with no significant side effects. Of those with total clinical resolution, 101 completed a 24-month follow-up with no relapses. Twenty-four (16%) children were nonrespondent. No apparent correlation between treatment response and age, gender, anatomic site, lesion type, or atopy was found. Contact immunotherapy with SADBE is a relatively safe and effective alternative treatment in the management of multiple and resistant cutaneous warts in children.
我们评估了二丁基方酸酯（SADBE）接触免疫疗法对188例儿童疣的治疗效果。纳入该研究的儿童需满足以下至少两条标准：有多个疣的单个或多个部位、对反复的药物和/或手术治疗有抵抗性的疣、复发性多个疣、以及患者或家长拒绝接受破坏性或手术治疗。研究排除了仅有单个疣或仅面部有扁平疣的儿童以及年龄小于2岁的儿童。治疗方法为每周两次应用SADBE系列稀释液（0.03 - 3%），持续不超过10周。在完成研究的148例儿童中，124例（84%）临床完全消退，且无明显副作用。在临床完全消退的儿童中，101例完成了24个月的随访，无复发。24例（16%）儿童无反应。未发现治疗反应与年龄、性别、解剖部位、病变类型或特应性之间存在明显相关性。SADBE接触免疫疗法是治疗儿童多发性和难治性皮肤疣的一种相对安全有效的替代疗法。
